Novozyme Lactase Variants for Dairy, US20260109961A1
Summary
USPTO published patent application US20260109961A1, filed 2025-06-06 by Novozymes A/S (Denmark), covering novel lactase enzyme variants with modified galactose inhibition profiles. The variants are described as suitable for producing low-lactose or lactose-free dairy products. CPC classifications include C12N 9/2471 (amylases or glucoinosidases), A23C 9/1206 (lactose reduction), and C12N 15/52/63 (gene sequences and expression vectors). Inventors include Roland Alexander Pache, Anders Gunnar Sandstrom, Jan Kjoelhede Vester, Henrik Friis-Madsen, and Dorota Nissen. As a published application, no enforcement or compliance obligations arise from this document.
“The present invention relates to novel lactase variants having improved properties relative to the parent lactase, such as decreased galactose inhibition or increased galactose inhibition.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 236 changes logged to date.
What changed
USPTO published patent application US20260109961A1 for novel lactase enzyme variants with altered galactose inhibition properties relative to the parent lactase. The application covers isolated DNA sequences encoding the variants, expression vectors, host cells, and methods of using the lactase variants for dairy product production.
Affected parties include food enzyme manufacturers, dairy processors, and biotechnology companies developing lactose-reduced or lactose-free products. No compliance obligations arise from publication of the application itself; the IP rights described will only become enforceable upon patent grant. Competitors developing similar lactase engineering approaches should review the claims for potential freedom-to-operate implications once the application matures to grant.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
POLYPEPTIDE VARIANTS
Application US20260109961A1 Kind: A1 Apr 23, 2026
Assignee
NOVOZYMES A/S
Inventors
Roland Alexander PACHE, Anders Gunnar SANDSTROM, Jan Kjoelhede VESTER, Henrik FRIIS-MADSEN, Dorota NISSEN
Abstract
The present invention relates to novel lactase variants having improved properties relative to the parent lactase, such as decreased galactose inhibition or increased galactose inhibition. The variants of the invention are suitable for production of dairy products, such as low-lactose dairy products or lactose-free dairy products. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the lactase variants of the invention.
CPC Classifications
C12N 9/2471 A23C 9/1206 C12N 15/52 C12N 15/63 C12Y 302/01023
Filing Date
2025-06-06
Application No.
19230791
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.